Literature DB >> 15964548

Characterization of the PR domain of RIZ1 histone methyltransferase.

Céline Derunes1, Klára Briknarová, Liqing Geng, Sheng Li, Chris R Gessner, Krissi Hewitt, ShuangDing Wu, Shi Huang, Virgil I Woods, Kathryn R Ely.   

Abstract

RIZ1 (PRDM2) and PRDI-BF1 (PRDM1) are involved in B cell differentiation and the development of B cell lymphomas. These proteins are expressed in two forms that differ by the presence or absence of a PR domain. The protein product that retains the PR domain is anti-tumorigenic while the product that lacks the PR domain is oncogenic and over-expressed in tumor cells. The conserved PR domain is homologous to the SET domain from a family of histone methyltransferases. RIZ1 is also a histone methyltransferase and methylates lysine 9 in histone H3. This activity has been mapped to the PR domain. In the present study, deuterium exchange mass spectrometry was used to define the structural boundaries of the RIZ1 PR domain and to map sites of missense mutations that occur in human cancers and reduce methyltransferase activity. Flexible segments were selectively deleted to produce protein products that crystallize for structural studies. Segments at the carboxyl terminus of the PR domain that are involved in methylation of H3 were shown to be flexible, similar to SET domains, suggesting that the PR and SET methyltransferases may belong to an emerging class of proteins that contain mobile functional regions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964548     DOI: 10.1016/j.bbrc.2005.05.190

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

Review 1.  Epigenetic alterations in human parathyroid tumors.

Authors:  Chiara Verdelli; Irene Forno; Valentina Vaira; Sabrina Corbetta
Journal:  Endocrine       Date:  2015-02-27       Impact factor: 3.633

2.  Variety is the splice of life.

Authors:  Anne Hamik; Mukesh K Jain
Journal:  J Mol Cell Cardiol       Date:  2007-09-29       Impact factor: 5.000

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 4.  Nonhistone Lysine Methylation in the Regulation of Cancer Pathways.

Authors:  Scott M Carlson; Or Gozani
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

5.  t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.

Authors:  Julie Damgaard Sandahl; Eva A Coenen; Erik Forestier; Jochen Harbott; Bertil Johansson; Gitte Kerndrup; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Jean-Michel Cayuela; Lucy Chilton; Maarten Fornerod; Valérie de Haas; Christine J Harrison; Hiroto Inaba; Gertjan J L Kaspers; Der-Cherng Liang; Franco Locatelli; Riccardo Masetti; Christine Perot; Susana C Raimondi; Katarina Reinhardt; Daisuke Tomizawa; Nils von Neuhoff; Marco Zecca; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Henrik Hasle
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

6.  Synergism between RIZ1 gene therapy and paclitaxel in SiHa cervical cancer cells.

Authors:  H Y Cheng; T Zhang; Y Qu; W J Shi; G Lou; Y X Liu; Y Y Zhang; L Cheng
Journal:  Cancer Gene Ther       Date:  2016-10-07       Impact factor: 5.987

Review 7.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

8.  Construction of PR domain eukaryotic expression vector and its inhibitory effect on esophageal cancer cells.

Authors:  Yuan Chen; Peng Zhang; Yuanguo Wang; Shangwen Dong; Yimei Liu
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

Review 9.  Chromatin-modifying enzymes as therapeutic targets--Part 1.

Authors:  Brian R Keppler; Trevor K Archer
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

10.  Histone Modifier Genes Alter Conotruncal Heart Phenotypes in 22q11.2 Deletion Syndrome.

Authors:  Tingwei Guo; Jonathan H Chung; Tao Wang; Donna M McDonald-McGinn; Wendy R Kates; Wanda Hawuła; Karlene Coleman; Elaine Zackai; Beverly S Emanuel; Bernice E Morrow
Journal:  Am J Hum Genet       Date:  2015-11-19       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.